Elixir Medical is also working on LithiX Hertz Contact Intravascular Lithotripsy (IVL) System for calcium fragmentation in moderate to severe calcified coronary artery lesions during PCI procedure.

Elixir Medical has joined the growing intravascular lithotripsy (IVL) market following the CE marking of its LithiX Hertz Contact system. The LithiX device employs focal stress contact points to ...

MILPITAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced EU MDR CE Mark approval and commercial ...

In search of a better solution than stents, Elixir Medical has developed the DynamX, which has three helical strands linked together. It is coated in a biodegradable polymer that releases a ...

WASHINGTON, D.C. — Oct. X, 2024 — Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced positive six-month data from the PINNACLE I study ...

Receipt of EU MDR CE mark may not be a magic potion, but Elixir Medical Corp. is certainly feeling a boost from the regulatory nod for its mechanical Lithix hertz contact intravascular lithotripsy ...

BIOADAPTOR RCT trial is the third trial of Elixir Medical’s robust DynamX ® bioadaptor clinical evidence program consisting of nine company-sponsored and investigator-initiated studies ...

(Circulation: Cardiovascular Interventions) The DynamX coronary bioadaptor continued to perform well 3 years into the BIOADAPTOR trial, as announced by Elixir Medical. CytoSorbents shared more ...

MILPITAS, Calif., March 18, 2025--(BUSINESS WIRE)--Elixir Medical is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025. This year’s list ...